摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(3-methyl-4-nitrophenyl)benzothiazole | 247080-48-4

中文名称
——
中文别名
——
英文名称
2-(3-methyl-4-nitrophenyl)benzothiazole
英文别名
2-(3-Methyl-4-nitrophenyl)-1,3-benzothiazole
2-(3-methyl-4-nitrophenyl)benzothiazole化学式
CAS
247080-48-4
化学式
C14H10N2O2S
mdl
——
分子量
270.312
InChiKey
GFGIWCWWBFPAFR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    174-176 °C
  • 沸点:
    451.3±55.0 °C(Predicted)
  • 密度:
    1.353±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.5
  • 重原子数:
    19
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.07
  • 拓扑面积:
    87
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(3-methyl-4-nitrophenyl)benzothiazole 在 palladium 10% on activated carbon 、 氢气 作用下, 以 二氯甲烷 为溶剂, 生成 2-(4'-amino-3'-methylphenyl)-benzothiazole
    参考文献:
    名称:
    Design, synthesis and antimetastatic evaluation of 1-benzothiazolylphenylbenzotriazoles for photodynamic therapy in oral cancer cells
    摘要:
    我们设计并合成了一系列新的1-苯并噻唑基苯基三唑类化合物 9a–p 并研究了它们在口腔癌细胞Ca9-22中通过UVA诱导的光敏作用参与的抗转移机制。
    DOI:
    10.1039/c6md00034g
  • 作为产物:
    描述:
    N-(phenyl)-3-methyl-4-nitrobenzamide劳森试剂 、 sodium hydroxide 、 potassium hexacyanoferrate(III) 作用下, 以 氯苯 为溶剂, 生成 2-(3-methyl-4-nitrophenyl)benzothiazole
    参考文献:
    名称:
    Design, synthesis and antimetastatic evaluation of 1-benzothiazolylphenylbenzotriazoles for photodynamic therapy in oral cancer cells
    摘要:
    我们设计并合成了一系列新的1-苯并噻唑基苯基三唑类化合物 9a–p 并研究了它们在口腔癌细胞Ca9-22中通过UVA诱导的光敏作用参与的抗转移机制。
    DOI:
    10.1039/c6md00034g
点击查看最新优质反应信息

文献信息

  • SYNTHESIS OF 2-(4-AMINOPHENYL) BENZOTHIAZOLE DERIVATIVES AND USE THEREOF
    申请人:Wang Jeh-Jeng
    公开号:US20120215154A1
    公开(公告)日:2012-08-23
    The present invention provides a method of preparing a compound of formula 6 comprising: (a) reacting a compound of formula 1 with a compound of formula 2 to form a compound of formula 3 wherein X of formula 2 is Cl or OH; (b) treating the compound formula 3 with Lawesson's reagent to form a compound of formula 4 (c) reacting a compound of formula 4 with potassium ferricyanide to produce a compound of formula 5 and (d) performing catalytic reduction of nitro group of the compound of formula 5 with palladium on charcoal to generate the compound of formula 6, wherein R 1 of formulae 1-6 is H, C 1-10 alkyl, C 1-10 alkoxy or C 1-10 haloalkyl, and R 2 of formulae 1-6 is H or C 1-10 alkyl. The present invention also provides a photodynamic therapy to a patient having at least one tumor comprising the steps of: administering a compound of formula 6 (wherein R 1 and R 2 are defined as the above) in a pharmaceutically acceptable carrier to the patient; waiting for a sufficient time to allow the administered compound to be taken up by a target tissue having the at least one tumor; and irradiating a region of the patient containing the target tissue; wherein growth of the tumor is inhibited.
    本发明提供了一种制备6式化合物的方法,包括:(a) 将1式化合物与2式化合物反应以形成3式化合物,其中2式化合物的X为Cl或OH;(b) 用Lawesson试剂处理3式化合物以形成4式化合物;(c) 将4式化合物与氰化亚铁钾反应以生成5式化合物;(d) 用活性炭上的钯进行5式化合物的硝基团的催化还原,生成6式化合物,其中1-6式中的R1为H、C1-10烷基、C1-10烷氧基或C1-10卤代烷基,1-6式中的R2为H或C1-10烷基。本发明还提供了一种对患有至少一种肿瘤的患者进行光动力疗法的方法,包括以下步骤:向患者投药物学可接受的载体中的6式化合物(其中R1和R2如上所定义);等待足够的时间以使给药的化合物被目标组织(至少一种肿瘤)吸收;照射患者身体含有目标组织的区域;从而抑制肿瘤的生长。
  • Synthesis, and biological evaluation of 2-(4-aminophenyl)benzothiazole derivatives as photosensitizing agents
    作者:Wan-Ping Hu、Yin-Kai Chen、Chao-Cheng Liao、Hsin-Su Yu、Yi-Min Tsai、Shu-Mei Huang、Feng-Yuan Tsai、Ho-Chuan Shen、Long-Sen Chang、Jeh-Jeng Wang
    DOI:10.1016/j.bmc.2010.04.082
    日期:2010.8
    Photodynamic therapy (PDT) employing exogenous photosensitizers is currently being approved for treatment of basal cell carcinoma (BCC). 2-(4-Aminophenyl)benzothiazoles (6) consist of chromophoric structure and absorb light in the UVA (315–400 nm). These results encouraged us to design and synthesize a diversity of 2-phenylbenzothiazoles (6). Studies on the apoptotic mechanism involved in photosensitive effects
    使用外源光敏剂的光动力疗法(PDT)目前已被批准用于治疗基底细胞癌(BCC)。2-(4-氨基苯基)苯并噻唑(6)由发色结构组成,可吸收UVA(315-400 nm)中的光。这些结果鼓励我们设计和合成各种2-苯基苯并噻唑(6)。在本文中研究了UVC激活的6在BCC细胞中诱导的光敏效应所涉及的凋亡机制。用6 -UVA处理的细胞显示出一些凋亡特征,包括亚G1群体的增加,膜联蛋白V结合的显着增加以及caspase-3的激活。6-UVA诱导线粒体膜电位(Δ降低ψ公吨),并通过增强的ROS产生和胞外信号调节激酶(ERK)和p38 MAPK表达的促进磷酸ATP。这些结果表明6- UVA在涉及ERK和p38活化的线粒体过程中引起光敏作用,并最终导致BCC细胞凋亡。
  • Chemistry of Ring-Substituted 4-(Benzothiazol-2-yl)phenylnitrenium Ions from Antitumor 2-(4-Aminophenyl)benzothiazoles
    作者:Yang Zhang、Mrinal Chakraborty、Christian G. Cerda-Smith、Ryan N. Bratton、Natalie E. Maurer、Ethan M. Senser、Michael Novak
    DOI:10.1021/jo400826f
    日期:2013.7.19
    long-lived (530 ns) nitrenium ion 11a by hydrolysis or photolysis in water. In this study, azide trapping shows that 9b–g generate 11b–g via rate-limiting N–O heterolysis. Ion lifetimes, estimated from azide/solvent selectivities, range from 250 to 1150 ns with identical lifetimes for 11a and 11f. Differences in biological activity of the amines are likely not due to differences in the chemistry of the cations
    2-(4-氨基苯基)苯并噻唑的环取代衍生物1a , 1b – g正在开发中作为抗肿瘤剂。一种衍生物1f已作为前药2f Phortress (NSC 710305)进入 1 期临床试验。这些胺被 CYP450 1A1 激活,显然转化为羟胺8a - g,它们很可能被代谢成酯,这些酯电离成负责细胞损伤的氮烯离子。之前我们展示了9a,即8a的乙酸酯,产生长寿命 (530 ns) 氮鎓离子11a在水中水解或光解。在这项研究中,叠氮化物捕集显示,图9b -克生成11B -克通过限速N-O heterolysis。根据叠氮化物/溶剂选择性估计的离子寿命范围为 250 到 1150 ns,11a和11f 的寿命相同。胺的生物活性的差异可能不是由于阳离子化学的差异,而是由于单个胺的代谢活化/失活的差异。与氮烯离子不同,酯的寿命强烈依赖于 3'-Me 取代基。含有 3'-Me 的酯 ( 9b , 9f , 9g)
  • SYNTHESIS AND ANTITUMOR ACTIVITY OF NOVEL BIS(BENZYLIDENE-BENZENAMINE)DISULFIDES
    申请人:WANG JEH-JENG
    公开号:US20120283475A1
    公开(公告)日:2012-11-08
    Novel synthetic bis(benzylidene-benzenamine)disulfides and the preparation method are disclosed in the present invention. These compounds are afforded with the oxidizing reagent at low temperature and short time period via intra-molecular coupling reaction. In vitro experiments have been revealed that bis-disulfides are cytotoxic to cancer cells, especially human breast cancer cells MCF-7. Additionally, bis-disulfides arrest the cell cycle at sub-G1 phase and increase p38 phosphorylation to result in apoptosis. Bis-disulfides also inhibit growth of murine melanoma B16 cells but have no cytotoxicity to human fibroblasts. Bis-disulfides also can reduce murine melanoma size in the mouse model. The prepared compounds of the invention would be applicable in anti-cancer and anti-tumor therapies.
    本发明公开了一种新型合成双(苯亚甲基苯胺)二硫化物及其制备方法。这些化合物通过分子内偶联反应在低温短时间内得到氧化试剂的作用下。体外实验表明,双二硫化物对癌细胞,特别是人类乳腺癌细胞MCF-7具有细胞毒性。此外,双二硫化物能够使细胞周期停留在亚G1期,并增加p38磷酸化,导致细胞凋亡。双二硫化物也能够抑制小鼠黑色素瘤B16细胞的生长,但对人类成纤维细胞没有细胞毒性。双二硫化物也能够减小小鼠模型中的黑色素瘤大小。本发明所制备的化合物可应用于抗癌和抗肿瘤治疗。
  • TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
    申请人:Wynne Graham Michael
    公开号:US20090075938A1
    公开(公告)日:2009-03-19
    There are disclosed compound of Formula (1): A 1 , A 2 , A 3 and A 4 which may be the same or different, represent N or CR 1 , X is a divalent group selected from O, S(O) n , C═W, NR 4 , NC(═O)R 5 and CR 6 R 7 , W is O, S, NR 20 , Y is N or CR 8 , one of R 4 , R 5 , R 6 , R 8 , R 9 and NR 20 represents -L-R 3 , in which L is a single bond or a linker group, additionally, R 1 , R 3 -R 9 , which may be the same or different, independently represent hydrogen or a substituent and R 20 represents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO 2 , NR 30 R 31 , in which R 30 and R 31 , which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of R 30 and R 31 may represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent pair of A 1 -A 4 each represent CR 1 , then the adjacent carbon atoms, together with their substituents may form a ring B, when X is CR 6 R 7 , R 6 and R 7 , together with the carbon atom to which they are attached may form a ring C, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia.
    公式(1)的化合物被揭示:A1,A2,A3和A4,它们可以相同或不同,代表N或CR1,X是从O,S(O)n,C═W,NR4,NC(═O)R5和CR6R7中选择的二价基团,W是O,S,NR20,Y是N或CR8,R4,R5,R6,R8,R9和NR20中的一个表示-L-R3,在其中L是单键或连接基团,此外,R1,R3-R9可以相同或不同,独立地表示氢或取代基,R20表示氢,羟基,可以用芳基取代的烷基,可以用芳基取代的烷氧基,芳基,CN,可以用芳基取代的烷氧基,可以用芳基取代的芳氧基,可以用取代基取代的烷酰基,可以用取代基取代的芳酰基,NO2,NR30R31,在其中R30和R31可以相同或不同,表示氢,可选地取代的烷基或可选地取代的芳基;此外,R30和R31中的一个可以表示可选地取代的烷酰基或可选地取代的芳酰基,n表示从0到2的整数,另外,当相邻的A1-A4中的一对表示CR1时,那么相邻的碳原子及其取代基可以形成环B,当X为CR6R7时,R6和R7与它们附着的碳原子一起可以形成环C,或其药学上可接受的盐,在制造用于治疗和/或预防杜氏肌萎缩症,贝克肌萎缩症或消瘦症的药物时使用。
查看更多

同类化合物

(1Z)-1-(3-乙基-5-羟基-2(3H)-苯并噻唑基)-2-丙酮 齐拉西酮砜 阳离子蓝NBLH 阳离子荧光黄4GL 锂2-(4-氨基苯基)-5-甲基-1,3-苯并噻唑-7-磺酸酯 铜酸盐(4-),[2-[2-[[2-[3-[[4-氯-6-[乙基[4-[[2-(硫代氧代)乙基]磺酰]苯基]氨基]-1,3,5-三嗪-2-基]氨基]-2-(羟基-kO)-5-硫代苯基]二氮烯基-kN2]苯基甲基]二氮烯基-kN1]-4-硫代苯酸根(6-)-kO]-,(1:4)氢,(SP-4-3)- 铜羟基氟化物 钾2-(4-氨基苯基)-5-甲基-1,3-苯并噻唑-7-磺酸酯 钠3-(2-{(Z)-[3-(3-磺酸丙基)-1,3-苯并噻唑-2(3H)-亚基]甲基}[1]苯并噻吩并[2,3-d][1,3]噻唑-3-鎓-3-基)-1-丙烷磺酸酯 邻氯苯骈噻唑酮 西贝奈迪 螺[3H-1,3-苯并噻唑-2,1'-环戊烷] 螺[3H-1,3-苯并噻唑-2,1'-环己烷] 葡萄属英A 草酸;N-[1-[4-(2-苯基乙基)哌嗪-1-基]丙-2-基]-2-丙-2-基氧基-1,3-苯并噻唑-6-胺 苯酰胺,N-2-苯并噻唑基-4-(苯基甲氧基)- 苯酚,3-[[2-(三苯代甲基)-2H-四唑-5-基]甲基]- 苯胺,N-(3-苯基-2(3H)-苯并噻唑亚基)- 苯碳杂氧杂脒,N-1,2-苯并异噻唑-3-基- 苯甲基2-甲基哌啶-1,2-二羧酸酯 苯并噻唑正离子,2-[3-(1,3-二氢-1,3,3-三甲基-2H-吲哚-2-亚基)-1-丙烯-1-基]-3-乙基-,碘化(1:1) 苯并噻唑正离子,2-[(2-乙氧基-2-羰基乙基)硫代]-3-甲基-,溴化 苯并噻唑啉 苯并噻唑-d4 苯并噻唑-6-腈 苯并噻唑-5-羧酸 苯并噻唑-5-硼酸频哪醇酯 苯并噻唑-4-醛 苯并噻唑-4-乙酸 苯并噻唑-2-磺酸钠 苯并噻唑-2-磺酸 苯并噻唑-2-磺酰氟 苯并噻唑-2-甲醛 苯并噻唑-2-甲酸 苯并噻唑-2-甲基甲胺 苯并噻唑-2-基磺酰氯 苯并噻唑-2-基叠氮化物 苯并噻唑-2-基-邻甲苯-胺 苯并噻唑-2-基-己基-胺 苯并噻唑-2-基-(4-氯-苯基)-胺 苯并噻唑-2-基-(4-氟-苯基)-胺 苯并噻唑-2-基-(4-乙氧基-苯基)-胺 苯并噻唑-2-基-(2-甲氧基-苯基)-胺 苯并噻唑-2-基-(2,6-二甲基-苯基)-胺 苯并噻唑-2-基(对甲苯基)甲醇 苯并噻唑-2-乙酸甲酯 苯并噻唑-2-乙腈 苯并噻唑-2(3H)-酮N2-[1-(吡啶-4-基)乙亚基]腙 苯并噻唑-2 - 丙基 苯并噻唑,6-(3-乙基-2-三氮烯基)-2-甲基-(8CI)